Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
17
11
2020
accepted:
18
02
2021
revised:
01
02
2021
pubmed:
13
3
2021
medline:
16
6
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are presented herein. Patients who had received ≥2 years of frontline nilotinib therapy and achieved MR
Identifiants
pubmed: 33707652
doi: 10.1038/s41375-021-01205-5
pii: 10.1038/s41375-021-01205-5
pmc: PMC8102196
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Pyrimidines
0
nilotinib
F41401512X
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1344-1355Références
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–93.
pubmed: 26688093
pmcid: 4884053
doi: 10.1016/S2352-3026(15)00048-4
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.
pubmed: 27325849
doi: 10.1200/JCO.2015.66.2866
Thielen N, Visser O, Ossenkoppele G, Janssen J. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol. 2016;97:145–54.
pubmed: 26519944
doi: 10.1111/ejh.12695
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.
pubmed: 28804124
pmcid: 5668495
doi: 10.1038/leu.2017.253
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
pubmed: 32127639
pmcid: 7214240
doi: 10.1038/s41375-020-0776-2
Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N. Engl J Med. 2019;381:1378–86.
pubmed: 31577882
doi: 10.1056/NEJMsr1905447
Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Long-term BCR-ABL1 tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Anticancer Res. 2015;35:6355–64.
pubmed: 26637844
Mahon FX. Treatment-free remission in CML: who, how, and why? Hematol Am Soc Hematol Educ Program. 2017;2017:102–9.
doi: 10.1182/asheducation-2017.1.102
Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346–57.
pubmed: 30394563
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440-53.
Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–11.
pubmed: 24366936
doi: 10.1200/JCO.2013.52.9123
Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–3.
pubmed: 25071107
doi: 10.1200/JCO.2014.55.6910
Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31.
pubmed: 28218239
pmcid: 5508077
doi: 10.1038/leu.2017.63
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients with Chronic Myeloid Leukemia. J Clin Oncol. 2017;35:298–305.
pubmed: 28095277
doi: 10.1200/JCO.2016.68.2914
Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.
pubmed: 20965785
doi: 10.1016/S1470-2045(10)70233-3
Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–54.
pubmed: 27932374
doi: 10.1182/blood-2016-09-742205
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.
pubmed: 24323036
doi: 10.1200/JCO.2012.48.5797
Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88:449–54.
pubmed: 23440689
doi: 10.1002/ajh.23427
Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528–35.
pubmed: 26686407
doi: 10.1016/S2352-3026(15)00196-9
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515–22.
pubmed: 23704092
doi: 10.1182/blood-2013-02-483750
Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18:353–60.e1.
pubmed: 29610029
doi: 10.1016/j.clml.2018.03.004
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375–e83.
pubmed: 31201085
doi: 10.1016/S2352-3026(19)30094-8
Chen KK, Du TF, Xiong PS, Fan GH, Yang W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Front Oncol. 2019;9:372.
pubmed: 31139566
pmcid: 6527744
doi: 10.3389/fonc.2019.00372
Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144:945–54.
pubmed: 29468438
pmcid: 5916993
doi: 10.1007/s00432-018-2604-x
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4:e310–e6.
pubmed: 28566209
doi: 10.1016/S2352-3026(17)30066-2
Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461–70.
pubmed: 29459949
doi: 10.7326/M17-1094
Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM, et al. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood. 2019;134:85–9.
pubmed: 30967368
doi: 10.1182/blood.2019000120
Cortes JE, Jean Khoury H, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91:606–16.
pubmed: 26971533
pmcid: 5548463
doi: 10.1002/ajh.24360
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34:2333–40.
pubmed: 27217448
pmcid: 5118045
doi: 10.1200/JCO.2015.64.8899
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.
pubmed: 26837842
pmcid: 4858585
doi: 10.1038/leu.2016.5
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71.
pubmed: 27121688
pmcid: 4991363
doi: 10.1038/leu.2016.104
Ross DM, Arthur C, Burbury K, Ko BS, Mills AK, Shortt J, et al. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Intern Med J. 2018;48:5–13.
pubmed: 29388307
doi: 10.1111/imj.13716
Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–47.
pubmed: 27133824
pmcid: 4980559
doi: 10.1038/leu.2016.115
Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, et al. Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget. 2018;9:7534–40.
pubmed: 29484130
doi: 10.18632/oncotarget.23691
Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, et al. MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica. 2019;104:2206–14.
pubmed: 30923102
pmcid: 6821602
doi: 10.3324/haematol.2018.214809